Retrospective Study
Copyright ©The Author(s) 2017.
World J Hepatol. Jan 8, 2017; 9(1): 48-56
Published online Jan 8, 2017. doi: 10.4254/wjh.v9.i1.48
Figure 1
Figure 1 Complete virological suppression and partial virological suppression at on treatment time points. The proportion of patients who achieve complete virological suppression (HBV DNA < 20 IU/mL) or partial virological suppression (HBV DNA 20-2000 IU/mL) while on tenofovir therapy. The number of patients followed up at each time point is recorded below the Time axis. HBV: Hepatitis B virus.
Figure 2
Figure 2 Survival analysis of the influence of treatment experience on complete virological suppression. A: Time to virological suppression according to duration of treatment, n = 92; B: Amongst treatment naïve patients n = 54; C: Treatment experienced patients, n = 37; D: Treatment experienced viraemic patients, n = 20. Number at risk describes the number of target group patients captured at each time period.